Kymera Therapeutics (KYMR) Set to Announce Earnings on Thursday

Kymera Therapeutics (NASDAQ:KYMR) is scheduled to be announcing its earnings results before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of ($0.73) per share for the quarter.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, February 22nd. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.19. The business had revenue of $47.90 million for the quarter, compared to analyst estimates of $41.94 million. Kymera Therapeutics had a negative net margin of 187.00% and a negative return on equity of 34.83%. Kymera Therapeutics’s revenue for the quarter was up 197.5% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.60) earnings per share. On average, analysts expect Kymera Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Kymera Therapeutics Trading Up 0.9 %

KYMR stock traded up $0.31 during midday trading on Friday, hitting $33.66. The stock had a trading volume of 54,646 shares, compared to its average volume of 725,020. Kymera Therapeutics has a 1-year low of $9.60 and a 1-year high of $45.31. The firm has a market cap of $2.06 billion, a P/E ratio of -13.36 and a beta of 2.27. The business has a fifty day moving average price of $39.02 and a two-hundred day moving average price of $28.41.

Insider Buying and Selling

In related news, major shareholder Venture Fund X. L.P. Atlas sold 42,302 shares of the firm’s stock in a transaction that occurred on Monday, March 11th. The shares were sold at an average price of $42.85, for a total value of $1,812,640.70. Following the transaction, the insider now owns 4,925,812 shares of the company’s stock, valued at $211,071,044.20. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Kymera Therapeutics news, major shareholder Venture Fund X. L.P. Atlas sold 115,090 shares of the business’s stock in a transaction on Wednesday, March 13th. The shares were sold at an average price of $42.23, for a total transaction of $4,860,250.70. Following the transaction, the insider now owns 4,676,075 shares in the company, valued at $197,470,647.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Venture Fund X. L.P. Atlas sold 42,302 shares of the business’s stock in a transaction on Monday, March 11th. The shares were sold at an average price of $42.85, for a total transaction of $1,812,640.70. Following the sale, the insider now directly owns 4,925,812 shares of the company’s stock, valued at $211,071,044.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 474,051 shares of company stock valued at $19,624,211. 16.67% of the stock is owned by insiders.

Analyst Ratings Changes

KYMR has been the topic of several analyst reports. Wolfe Research initiated coverage on shares of Kymera Therapeutics in a report on Thursday, February 15th. They set a “peer perform” rating on the stock. Oppenheimer began coverage on shares of Kymera Therapeutics in a research note on Monday. They issued an “outperform” rating and a $53.00 target price on the stock. Bank of America cut shares of Kymera Therapeutics from a “buy” rating to a “neutral” rating and dropped their target price for the company from $45.00 to $30.00 in a research note on Wednesday, January 3rd. Piper Sandler boosted their target price on shares of Kymera Therapeutics from $39.00 to $56.00 and gave the company an “overweight” rating in a research note on Tuesday, February 27th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Kymera Therapeutics from $34.00 to $47.00 and gave the company an “overweight” rating in a research note on Friday, February 23rd. Six investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, Kymera Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $41.20.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.